Fulcrum Therapeutics, Inc. (FULC)
3.73
-0.04
(-1.06%)
USD |
NASDAQ |
Nov 16, 16:00
3.73
0.00 (0.00%)
After-Hours: 20:00
Fulcrum Therapeutics Enterprise Value : -12.85M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | -12.85M |
| November 12, 2026 | -19.73M |
| November 11, 2026 | -15.14M |
| November 10, 2026 | -16.67M |
| November 09, 2026 | -16.67M |
| November 06, 2026 | -18.20M |
| November 05, 2026 | -19.73M |
| November 04, 2026 | -12.85M |
| November 03, 2026 | -15.14M |
| November 02, 2026 | -22.02M |
| October 30, 2026 | -17.43M |
| October 29, 2026 | -12.85M |
| October 28, 2026 | -14.38M |
| October 27, 2026 | -18.20M |
| October 26, 2026 | -22.78M |
| October 23, 2026 | -19.73M |
| October 22, 2026 | -19.73M |
| October 21, 2026 | -18.20M |
| October 20, 2026 | -16.67M |
| October 19, 2026 | -18.20M |
| October 16, 2026 | -22.02M |
| October 15, 2026 | -20.49M |
| October 14, 2026 | -20.49M |
| October 13, 2026 | -19.73M |
| October 12, 2026 | -14.38M |
| Date | Value |
|---|---|
| October 09, 2026 | -12.85M |
| October 08, 2026 | -14.38M |
| October 07, 2026 | -20.49M |
| October 06, 2026 | -18.96M |
| October 05, 2026 | -17.43M |
| October 02, 2026 | -18.96M |
| October 01, 2026 | -19.73M |
| September 30, 2026 | -18.20M |
| September 29, 2026 | -31.31M |
| September 28, 2026 | -29.78M |
| September 25, 2026 | -28.26M |
| September 24, 2026 | -24.82M |
| September 23, 2026 | -22.92M |
| September 22, 2026 | -20.63M |
| September 21, 2026 | -23.68M |
| September 18, 2026 | -26.73M |
| September 17, 2026 | -25.97M |
| September 16, 2026 | -24.44M |
| September 15, 2026 | -25.20M |
| September 14, 2026 | -24.44M |
| September 11, 2026 | -23.68M |
| September 10, 2026 | -23.68M |
| September 09, 2026 | -20.63M |
| September 08, 2026 | -22.15M |
| September 04, 2026 | -19.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 12.61M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -104.09M |
| Definium Therapeutics, Inc. | 3.381B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.94M |
| Total Expenses (Quarterly) | 10.94M |
| EPS Diluted (Quarterly) | -0.1433 |
| Earnings Yield | -27.98% |
| Normalized Earnings Yield | -25.08 |